Guanfacine ER

• ADHD (Attention-Deficit/Hyperactivity Disorder)
• Pediatric ADHD
• Non-Stimulant ADHD Treatment
• Adjunctive ADHD Therapy

Guanfacine extended-release (Intuniv) is a selective alpha-2A adrenergic agonist FDA-approved for attention-deficit hyperactivity disorder in patients ages 6 to 17, used either as monotherapy or as adjunctive therapy with a stimulant. Unlike stimulants, it is not a controlled substance, has no abuse liability, and does not suppress appetite or directly disrupt sleep onset. It is particularly valuable when stimulants alone produce only partial response, when emotional dysregulation, oppositional behavior, tics, or comorbid anxiety dominate the clinical picture, or when stimulant side effects such as insomnia, weight loss, or rebound irritability limit dosing.

Mechanism of Action

Guanfacine is a selective post-synaptic alpha-2A adrenergic receptor agonist with roughly 15 to 20 times the affinity for alpha-2A over alpha-2B and 2C subtypes. Its therapeutic action in ADHD is anatomically specific: stimulation of post-synaptic alpha-2A receptors on the dendritic spines of pyramidal neurons in the dorsolateral prefrontal cortex closes hyperpolarization-activated cyclic nucleotide-gated (HCN) cation channels. This strengthens recurrent network signaling and protects working memory traces from interference, the precise neural circuit deficit demonstrated in ADHD on functional imaging.

Clinically, the mechanism translates into improved sustained attention, working memory, behavioral inhibition, and emotional regulation — outcomes that closely match the prefrontal cortex's executive role. The effect builds over weeks rather than minutes, which is why guanfacine ER produces gradual and durable changes rather than the rapid on/off pattern of stimulants. Its older application as an antihypertensive arises from a different population of alpha-2 receptors in the brainstem nucleus tractus solitarius, where activation reduces sympathetic outflow and lowers blood pressure and heart rate. The same brainstem mechanism explains the cardiovascular side effects clinicians monitor for. The NIMH overview of ADHD provides additional context on diagnosis and treatment frameworks.

Clinical Use

For most children and adolescents with uncomplicated ADHD, a stimulant such as methylphenidate is first-line because of larger effect sizes (Cohen's d roughly 0.9 for stimulants vs 0.7 for guanfacine ER). Guanfacine ER is preferred when the family declines a controlled substance, when prior stimulant trials produced intolerable side effects, when prominent tics, anxiety disorders, oppositional defiant disorder, or significant sleep-onset insomnia coexist, or when augmentation of a partial stimulant response is needed. The atomoxetine and clonidine ER are the other major non-stimulant options, each with different side-effect tradeoffs.

When used adjunctively with a morning stimulant, guanfacine ER often smooths the late-afternoon and evening hours when stimulant rebound is most disruptive — homework time, evening transitions, and bedtime. Patient selection should weigh baseline blood pressure, resting heart rate, and any history of syncope, bradyarrhythmia, or significant cardiac disease. Behavioral therapy and parent training remain foundational alongside medication; medication alone is rarely sufficient for the school and home accommodations most children also need. Comprehensive evaluation also screens for and treats common comorbidities including learning disabilities, autism spectrum disorder, mood and anxiety disorders, sleep disorders, and substance use, each of which can blunt or mimic ADHD symptom response. Family history of ADHD, response to prior medication trials, and parental preferences should be documented and revisited annually. Our psychiatric team often coordinates with school counselors and pediatric subspecialists when comorbidities make management complex, and we work with families to obtain school-based accommodations under Section 504 plans or IEPs when academic performance lags despite medication response.

How to Take It

The extended-release tablet must be swallowed whole — never crushed, chewed, broken, or split, because doing so destroys the controlled-release matrix and can cause a sudden burst of drug delivery with hypotension and sedation. Take it once daily at approximately the same time, either morning or evening; many families prefer evening dosing because the peak sedation falls during sleep. Do not take with a high-fat meal: a heavy fatty breakfast can increase peak drug exposure substantially and amplify side effects. If a dose is missed, skip it and resume the next day; do not double up.

The first week typically brings noticeable sedation, fatigue, mild light-headedness on standing, and sometimes a dry mouth or stomachache. These usually attenuate over 1 to 2 weeks as the body adjusts, which is why titration proceeds in 1 mg weekly increments rather than faster. Hydration helps with the orthostatic effects. Eating a small meal with the dose can also blunt early gastrointestinal complaints. Never stop the medication abruptly: rebound hypertension, tachycardia, and headache can occur, so taper by no more than 1 mg every 3 to 7 days under medical supervision when discontinuing. Travel and time-zone changes may temporarily disrupt dose timing; maintain consistent dosing as best as possible and avoid skipping doses, which is particularly disruptive for this medication.

Monitoring and Follow-Up

Baseline assessment includes a focused cardiac history, a personal and family history of sudden cardiac death or arrhythmia, blood pressure, and resting heart rate. An ECG is not routinely required but is reasonable when history suggests risk. Follow-up at 1 to 2 weeks reviews tolerability and checks blood pressure and heart rate; titrate by 1 mg per week to a target of 0.05 to 0.12 mg/kg/day, generally in the 1 to 4 mg range. Recheck blood pressure and heart rate at every dose change and at least every 3 months once stable.

Red numbers that warrant dose reduction or discontinuation include systolic blood pressure below the 5th percentile for age and height, heart rate persistently below 50 beats per minute in adolescents (lower thresholds in children adjusted for age), a 20 mmHg orthostatic drop, recurrent dizziness, syncope, or new chest pain. Standardized rating scales such as the Vanderbilt or SNAP-IV completed by parents and teachers should be reviewed at 4 to 6 weeks, then at least every 6 months, to confirm sustained benefit and inform dose adjustments. Growth, mood, and sleep quality are tracked at every visit. Annual fasting metabolic panel is reasonable but not mandatory. A planned medication holiday is generally not necessary for guanfacine ER as it is for stimulants, because there is no growth suppression effect and no daily diversion risk to manage.

Special Populations

Safety and efficacy are established for ages 6 through 17. The product has not been studied in adults for ADHD; immediate-release guanfacine is sometimes used off-label. Pregnancy data are limited; animal studies showed some developmental effects but no clear teratogenicity, and human use should follow a careful risk-benefit discussion. Guanfacine appears in breast milk and is generally avoided in lactation. Renal impairment with eGFR below 60 mL/min/1.73m^2 prolongs the half-life; the dose should be reduced and titrated more cautiously. Hepatic impairment also calls for slower titration and lower target doses. Strong CYP3A4 inhibitors such as ketoconazole roughly double exposure (cut the dose in half) while strong inducers such as rifampin can necessitate higher doses. Children with cardiac structural disease, conduction abnormalities, or syncope of unclear cause warrant cardiology input before starting. The FDA label for Intuniv details full prescribing information.

When to Contact Your Doctor

Seek emergency care for fainting, severe dizziness, chest pain, rapid or irregular heartbeat at rest, or seizure. Call within 24 hours for persistent dizziness on standing, daytime sedation severe enough to impair school performance or driving, blood pressure or pulse readings notably below baseline at home, or new mood changes including persistent sadness, irritability, or withdrawal. Any rash, swelling of the face or tongue, or trouble breathing is an allergic reaction warning sign. If the medication has been stopped abruptly for any reason, watch closely for headache, agitation, racing heart, or markedly elevated blood pressure over the next several days and contact the prescriber promptly. Sudden discontinuation is never advisable, and missed doses for more than 2 to 3 days warrant a discussion before resuming because re-titration may be needed.

If attention, behavior, or emotional regulation are interfering with school, friendships, or family life, contact us or schedule a visit so our team can confirm the diagnosis, design a comprehensive treatment plan that may combine medication with behavioral and educational supports, and decide whether guanfacine ER is the right component for your child.